Sumatriptan - GlaxoSmithKline

Drug Profile

Sumatriptan - GlaxoSmithKline

Alternative Names: Imigran Nasal Spray; Imitrex Nasal Spray

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine
  • No development reported Menstrual migraine

Most Recent Events

  • 22 Feb 2016 First Generic equivalent complex product Imitrex® nasal spray approved in USA for Migrane
  • 04 Oct 2013 Launched for Migraine in Argentina, Canada, Indonesia and Israel before 4 October 2013 under the trade name Imitrex® (Intranasal)
  • 02 Feb 2006 Registered for Migraine in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top